Shaanxi Fujie Pharmaceutical

Shaanxi Fujie Pharmaceutical Co., Ltd., established in 1993, is a leading Chinese high-tech enterprise specializing in the research, development, and large-scale production of licorice-derived active pharmaceutical ingredients (APIs) and plant extracts. The company manages a comprehensive supply chain that includes standardized cultivation bases in Xinjiang and Central Asia alongside modern GMP-certified manufacturing facilities in Shaanxi. Its core portfolio features high-purity small molecules such as Monoammonium Glycyrrhizinate and Enoxolone, which are utilized globally in the treatment of liver diseases, inflammatory conditions, and respiratory ailments. Beyond the pharmaceutical sector, Fujie Pharmaceutical is a major supplier to the cosmetic, food, and tobacco industries, maintaining a significant market presence in North America, Japan, and Korea. The firm is recognized for its expertise in extraction technology and its collaborative research with several prominent Chinese universities.